Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Permeability modes in fluctuating lipid membranes with DNA-translocating pores.

Moleiro LH, Mell M, Bocanegra R, López-Montero I, Fouquet P, Hellweg T, Carrascosa JL, Monroy F.

Adv Colloid Interface Sci. 2017 Sep;247:543-554. doi: 10.1016/j.cis.2017.07.009. Epub 2017 Jul 16.

PMID:
28735883
2.

Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Kadosh D, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Wiederhold NP, Patterson TF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6703-6708. doi: 10.1128/AAC.01144-16. Print 2016 Nov.

3.

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.

4.

The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF.

J Antimicrob Chemother. 2016 Mar;71(3):692-5. doi: 10.1093/jac/dkv398. Epub 2015 Nov 29.

5.

Characterization of the initial steps in the T7 DNA ejection process.

González-García VA, Bocanegra R, Pulido-Cid M, Martín-Benito J, Cuervo A, Carrascosa JL.

Bacteriophage. 2015 Jun 2;5(3):e1056904. eCollection 2015 Jul-Sep.

6.

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Matsumoto S, Bocanegra RA, Herrera ML, Wickes BL, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2015 May;59(5):2875-81. doi: 10.1128/AAC.04857-14. Epub 2015 Mar 9.

7.

Conformational changes leading to T7 DNA delivery upon interaction with the bacterial receptor.

González-García VA, Pulido-Cid M, Garcia-Doval C, Bocanegra R, van Raaij MJ, Martín-Benito J, Cuervo A, Carrascosa JL.

J Biol Chem. 2015 Apr 17;290(16):10038-44. doi: 10.1074/jbc.M114.614222. Epub 2015 Feb 19.

8.

Biophysical analysis of the MHR motif in folding and domain swapping of the HIV capsid protein C-terminal domain.

Bocanegra R, Fuertes MÁ, Rodríguez-Huete A, Neira JL, Mateu MG.

Biophys J. 2015 Jan 20;108(2):338-49. doi: 10.1016/j.bpj.2014.11.3472.

9.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

10.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

11.

Mechanical unfolding of long human telomeric RNA (TERRA).

Garavís M, Bocanegra R, Herrero-Galán E, González C, Villasante A, Arias-Gonzalez JR.

Chem Commun (Camb). 2013 Jul 21;49(57):6397-9. doi: 10.1039/c3cc42981d.

12.

Association equilibrium of the HIV-1 capsid protein in a crowded medium reveals that hexamerization during capsid assembly requires a functional C-domain dimerization interface.

Bocanegra R, Alfonso C, Rodríguez-Huete A, Fuertes MÁ, Jiménez M, Rivas G, Mateu MG.

Biophys J. 2013 Feb 19;104(4):884-93. doi: 10.1016/j.bpj.2012.12.035.

13.

Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF, Thornton CR.

J Clin Microbiol. 2013 Feb;51(2):459-65. doi: 10.1128/JCM.02142-12. Epub 2012 Nov 21.

14.

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.

15.

Molecular recognition in the human immunodeficiency virus capsid and antiviral design.

Bocanegra R, Rodríguez-Huete A, Fuertes MÁ, Del Álamo M, Mateu MG.

Virus Res. 2012 Nov;169(2):388-410. doi: 10.1016/j.virusres.2012.06.016. Epub 2012 Jun 21. Review.

PMID:
22728445
16.

A murine model of Cryptococcus gattii meningoencephalitis.

Thompson GR 3rd, Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Graybill JR, Patterson TF.

J Antimicrob Chemother. 2012 Jun;67(6):1432-8. doi: 10.1093/jac/dks060. Epub 2012 Feb 29.

17.

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.

Kirkpatrick WR, Najvar LK, Vallor AC, Wiederhold NP, Bocanegra R, Pfeiffer J, Perkins K, Kugler AR, Sweeney TD, Patterson TF.

J Antimicrob Chemother. 2012 Apr;67(4):970-6. doi: 10.1093/jac/dkr567. Epub 2012 Jan 11.

PMID:
22240402
18.

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF.

Clin Microbiol Infect. 2012 Feb;18(2):E20-3. doi: 10.1111/j.1469-0691.2011.03712.x. Epub 2011 Nov 30.

19.

Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity.

Bocanegra R, Nevot M, Doménech R, López I, Abián O, Rodríguez-Huete A, Cavasotto CN, Velázquez-Campoy A, Gómez J, Martínez MÁ, Neira JL, Mateu MG.

PLoS One. 2011;6(9):e23877. doi: 10.1371/journal.pone.0023877. Epub 2011 Sep 8.

20.

Larger helical populations in peptides derived from the dimerization helix of the capsid protein of HIV-1 results in peptide binding toward regions other than the "hotspot" interface.

Doménech R, Bocanegra R, González-Muñiz R, Gómez J, Mateu MG, Neira JL.

Biomacromolecules. 2011 Sep 12;12(9):3252-64. doi: 10.1021/bm2007168. Epub 2011 Jul 26.

PMID:
21761887
21.

The isolated major homology region of the HIV capsid protein is mainly unfolded in solution and binds to the intact protein.

Doménech R, Bocanegra R, Velázquez-Campoy A, Neira JL.

Biochim Biophys Acta. 2011 Oct;1814(10):1269-78. doi: 10.1016/j.bbapap.2011.06.011. Epub 2011 Jul 6.

PMID:
21745604
22.

Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2011 Jul;55(7):3254-60. doi: 10.1128/AAC.01750-10. Epub 2011 Apr 18.

23.

Effects of macromolecular crowding on the inhibition of virus assembly and virus-cell receptor recognition.

Rincón V, Bocanegra R, Rodríguez-Huete A, Rivas G, Mateu MG.

Biophys J. 2011 Feb 2;100(3):738-746. doi: 10.1016/j.bpj.2010.12.3714.

24.

Dendrimers as potential inhibitors of the dimerization of the capsid protein of HIV-1.

Doménech R, Abian O, Bocanegra R, Correa J, Sousa-Herves A, Riguera R, Mateu MG, Fernandez-Megia E, Velázquez-Campoy A, Neira JL.

Biomacromolecules. 2010 Aug 9;11(8):2069-78. doi: 10.1021/bm100432x.

PMID:
20690715
25.

Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.

Wiederhold NP, Najvar LK, Bocanegra R, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2010 Mar;54(3):1055-9. doi: 10.1128/AAC.01445-09. Epub 2010 Jan 11.

26.

Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis.

Wiederhold NP, Thornton CR, Najvar LK, Kirkpatrick WR, Bocanegra R, Patterson TF.

Clin Vaccine Immunol. 2009 Dec;16(12):1844-6. doi: 10.1128/CVI.00268-09. Epub 2009 Sep 30.

27.

Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Tolman JA, Wiederhold NP, McConville JT, Najvar LK, Bocanegra R, Peters JI, Coalson JJ, Graybill JR, Patterson TF, Williams RO 3rd.

Antimicrob Agents Chemother. 2009 Jun;53(6):2613-5. doi: 10.1128/AAC.01657-08. Epub 2009 Mar 16.

28.

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.

Brzankalski GE, Najvar LK, Wiederhold NP, Bocanegra R, Fothergill AW, Rinaldi MG, Pattterson TF, Graybill JR.

J Antimicrob Chemother. 2008 Nov;62(5):1094-100. doi: 10.1093/jac/dkn304. Epub 2008 Jul 25.

29.

Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2593-8. doi: 10.1128/AAC.00276-08. Epub 2008 May 12.

30.

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

Najvar LK, Bocanegra R, Wiederhold NP, Lambros C, Najarian N, Patterson TF, Graybill JR.

Clin Microbiol Infect. 2008 Jun;14(6):595-600. doi: 10.1111/j.1469-0691.2008.01994.x. Epub 2008 Apr 5.

31.

Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Vallor AC, Kirkpatrick WR, Bocanegra R, Molina D, Olivo M, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Mar;52(3):1176-8. Epub 2007 Dec 26.

32.

New guinea pig model of Cryptococcal meningitis.

Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill JR.

Antimicrob Agents Chemother. 2007 Aug;51(8):3011-3. Epub 2007 Jun 11.

33.

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO 3rd.

J Infect. 2007 Jul;55(1):68-74. Epub 2007 Mar 13.

PMID:
17360039
34.

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR.

Antimicrob Agents Chemother. 2007 May;51(5):1616-20. Epub 2007 Feb 16.

35.

Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, Kirkpatrick WR, Bocanegra R, Vallor AC, Patterson TF, Filler SG.

Antimicrob Agents Chemother. 2006 Oct;50(10):3501-3.

36.

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO 3rd.

Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4.

37.

Monodisperse structured multi-vesicle microencapsulation using flow-focusing and controlled disturbance.

Bocanegra R, Luis Sampedro J, Gañán-Calvo A, Marquez M.

J Microencapsul. 2005 Nov;22(7):745-59.

PMID:
16421085
38.

Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.

Bocanegra R, Najvar LK, Hernandez S, McCarthy DI, Graybill JR.

Antimicrob Agents Chemother. 2005 Dec;49(12):5139-41.

39.

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana.

Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR.

Antimicrob Agents Chemother. 2005 May;49(5):1701-7.

40.

Antifungal therapy of murine Aspergillus terreus infection.

Graybill JR, Hernandez S, Bocanegra R, Najvar LK.

Antimicrob Agents Chemother. 2004 Oct;48(10):3715-9.

41.

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jun;48(6):2288-91.

42.

Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Graybill JR.

Antimicrob Agents Chemother. 2004 Jun;48(6):2140-3.

43.
44.

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Najvar LK, Cacciapuoti A, Hernandez S, Halpern J, Bocanegra R, Gurnani M, Menzel F, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2004 Mar;48(3):758-64.

45.

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK.

J Antimicrob Chemother. 2003 Oct;52(4):656-62. Epub 2003 Sep 12.

PMID:
12972452
46.

Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.

Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA.

Antimicrob Agents Chemother. 2003 Jul;47(7):2373-5.

47.

Improving the mouse model for studying the efficacy of voriconazole.

Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R.

J Antimicrob Chemother. 2003 Jun;51(6):1373-6. Epub 2003 May 13.

PMID:
12746374
48.

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2003 Apr;47(4):1436-8.

49.

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2.

50.

In vitro and in vivo activities of posaconazole against Coccidioides immitis.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2002 May;46(5):1352-6.

Supplemental Content

Loading ...
Support Center